März, Winfried; Schmidt, Nina; An Haack, Ira; Dressel, Alexander; Grammer, Tanja B; Kleber, Marcus E; Baessler, Andrea; Beil, F Ulrich; Gouni-Berthold, Ioanna; Julius, Ulrich; Kassner, Ursula; Katzmann, Julius L; Klose, Gerald; König, Christel; Koenig, Wolfgang; Koschker, Ann-Cathrin; Laufs, Ulrich; Merkel, Martin; Otte, Britta; Parhofer, Klaus G; Hengstenberg, Wibke; Schunkert, Heribert; Stach-Jablonski, Ksenija; Steinhagen-Thiessen, Elisabeth; Olivier, Christoph B; Hahmann, Harry; Krzossok, Stefan; Vogt, Anja; Müller-Wieland, Dirk; Schatz, Ulrike     «

März, Winfried; Schmidt, Nina; An Haack, Ira; Dressel, Alexander; Grammer, Tanja B; Kleber, Marcus E; Baessler, Andrea; Beil, F Ulrich; Gouni-Berthold, Ioanna; Julius, Ulrich; Kassner, Ursula; Katzmann, Julius L; Klose, Gerald; König, Christel; Koenig, Wolfgang; Koschker, Ann-Cathrin; Laufs, Ulrich; Merkel, Martin; Otte, Britta; Parhofer, Klaus G; Hengstenberg, Wibke; Schunkert, Heribert; Stach-Jablonski, Ksenija; Steinhagen-Thiessen, Elisabeth; Olivier, Christoph B; Hahmann, Harry; Krzossok, St...     »

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, and few achieve the goals for low-density lipoprotein cholesterol (LDL-C). In this analysis of the German Cascade Screening and Registry for High Cholesterol (CaRe High), we examined the status of lipid management, treatment strategies, and LDL-C goal attainment according to the ESC/EAS dyslipidemia guidelines. METHODS: We evaluated consolidated datasets from 1501 FH patients diagnosed clinically and seen either by lipid specialists or general practitioners and internists. We conducted a questionnaire survey of both the recruiting physicians and patients. RESULTS: Among the 1501 patients, 86% regularly received lipid-lowering drugs. LDL-C goals were achieved by 26% and 10% of patients with atherosclerotic cardiovascular disease (ASCVD) according to the 2016 and 2019 ESC/EAS dyslipidemia guidelines, respectively. High intensity lipid-lowering was administered more often in men than in women, in patients with ASCVD, at higher LDL-C and in patients with a genetic diagnosis of FH. CONCLUSIONS: FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be associated with increased treatment intensity. Achieving the LDL-C goals of the 2019 ESC/EAS dyslipidemia guidelines remains challenging if pre-treatment LDL-C is very high.      «

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, and few achieve the goals for low-density lipoprotein cholesterol (LDL-C). In this analysis of the German Cascade Screening and Registry for High Cholesterol (CaRe High), we examined the status of lipid management, treatment strategies, and LDL-C goal attainment according to the ESC/EAS dyslipidemia guidelines. METHODS: We evalua...     »